Tag: benign prostatic hyperplasia treatment market forecast

Uncover key drivers, emerging technologies, and competitive movements shaping the benign prostatic hyperplasia treatment market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Benign Prostatic Hyperplasia Treatment Market expected to reach by 2030?

The benign prostatic hyperplasia treatment market size has demonstrated significant growth in the past few years. Projections indicate it will expand from $8.69 billion in 2025 to reach $9.17 billion by 2026, advancing at a compound annual growth rate (CAGR) of 5.6%. This historical growth is attributable to factors such as an increasing aging male population, a rising prevalence of urinary disorders, the expansion of urology specialty services, the growing use of pharmacological treatments, and improved access to diagnostic screening.

The benign prostatic hyperplasia treatment market size is projected to experience substantial expansion in the coming years, reaching $11.29 billion by 2030, driven by a compound annual growth rate (CAGR) of 5.3%. This anticipated growth during the forecast period is primarily driven by factors such as the increasing embrace of robotic-assisted prostate procedures, a heightened emphasis on personalized treatment strategies, the expansion of therapy choices available at home, the growing incorporation of digital patient monitoring tools, and an increasing need for minimally invasive interventions. Key trends expected over the forecast period encompass a greater adoption of minimally invasive surgical methods, a surging demand for targeted drug therapies, an increasing application of combination treatment protocols, the expansion of treatment options in outpatient settings, and an intensified focus on managing symptoms and improving patients’ quality of life.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21112&type=smp

What Drivers Are Driving Adoption Within The Benign Prostatic Hyperplasia Treatment Market?

The increasing acceptance of minimally invasive surgeries is anticipated to propel the growth of the benign prostatic hyperplasia treatment market in the coming years. Minimally invasive surgeries are procedures characterized by small or no incisions, employing specialized instruments to minimize recovery time, pain, and the risk of complications. This rise in adoption is driven by benefits like shorter recovery periods, reduced discomfort, lower chances of complications, and improved cosmetic outcomes. For benign prostatic hyperplasia treatment, minimally invasive surgeries offer patients quicker recovery times, reduced risks of complications, and effective symptom relief, leading to enhanced overall surgical results. For example, in September 2023, the American Society of Plastic Surgeons (ASPS), a U.S.-based professional association, reported that nearly 25.4 million minimally invasive cosmetic procedures were performed in 2023, which was up 7% from 23.7 million in 2022. Consequently, the growing adoption of minimally invasive surgeries is fueling the expansion of the benign prostatic hyperplasia treatment market.

How Is The Benign Prostatic Hyperplasia Treatment Market Organized Into Various Segments?

The benign prostatic hyperplasia treatment market covered in this report is segmented –

1) By Treatment: Minimal Invasive Surgery, Invasive Surgery

2) By Therapeutic Class: Alpha Blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Other Therapeutic classes

3) By End User: Home Healthcare, Hospitals And Clinics

Subsegments:

1) By Minimal Invasive Surgery: Transurethral Resection of the Prostate (TURP), Laser Surgery, Prostatic Urethral Lift, Transurethral Incision of the Prostate (TUIP), Microwave Therapy

2) By Invasive Surgery: Open Prostatectomy, Robotic Prostatectomy

Which Trends Are Guiding The Evolution Of The Benign Prostatic Hyperplasia Treatment Market?

Leading firms in the benign prostatic hyperplasia treatment market are concentrating on creating novel therapies, like intraprostatic drug elution therapy, to secure a competitive edge. This therapy entails inserting a bioabsorbable implant directly into the prostate gland for the sustained, localized delivery of a therapeutic substance. For example, in May 2025, Resurge Therapeutics, a US-based developer of urology technology, unveiled a paclitaxel-eluting bioabsorbable implant designed for BPH, which provides convenient office-based administration, precise drug delivery, and reduced post-procedure discomfort. Such localized administration minimizes systemic exposure, improves effectiveness, and helps maintain sexual function. Nevertheless, its long-term safety profile and widespread adoption are still being assessed.

Who Are The Prominent Global Companies Shaping The Benign Prostatic Hyperplasia Treatment Market Landscape?

Major companies operating in the benign prostatic hyperplasia treatment market are Astellas Pharma Inc., Bayer AG, Pfizer Inc., Merck & Co Inc., Eli Lilly and Company, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Sanofi S.A., Boston Scientific Corporation, Olympus Corporation, Teleflex Incorporated, Cook Medical Incorporated, Coloplast Group, Medtronic Public Limited Company, Urovant Sciences Ltd., UroGen Pharma Ltd., Urologix Inc., Zenflow Inc., HistoSonics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/benign-prostatic-hyperplasia-treatment-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Benign Prostatic Hyperplasia Treatment Market?

North America was the largest region in the benign prostatic hyperplasia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the benign prostatic hyperplasia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Benign Prostatic Hyperplasia Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21112&type=smp

Browse Through More Reports Similar to the Global Benign Prostatic Hyperplasia Treatment Market 2026, By The Business Research Company

Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-nuclear-medicine-diagnostics-global-market-report

Drugs For Benign Prostatic Hypertrophy Market Report 2026

https://www.thebusinessresearchcompany.com/report/drugs-for-benign-prostatic-hypertrophy-global-market-report

Prostate Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Is The Benign Prostatic Hyperplasia Treatment Market Expected To Grow In Terms Of Size?

In recent times, the market size for the treatment of benign prostatic hyperplasia has seen significant growth. The market, which was valued at $8.23 billion in 2024, is anticipated to increase to $8.69 billion in 2025, representing a compound annual growth rate (CAGR) of 5.5%. This growth over the historical period can be credited to factors such as increased awareness and screening initiatives, a rise in the prevalence of BPH, improved healthcare knowledge, enhancements in healthcare infrastructure, and an expanding elderly population.

The market for treatment of benign prostatic hyperplasia is expected to experience robust growth over the next few years, with predictions of reaching a market size of $10.74 billion by 2029, growing at a compound annual growth rate (CAGR) of 5.5%. Factors contributing to this projected growth include an increase in the use of less invasive procedures, an aging population, availability of advanced treatments, a greater emphasis on care that focuses on the patient, and a rise in the occurrence of accompanying health issues. Trends anticipated to be seen during this forecast period consist of the development of targeted treatment approaches, implementation of digital health solutions, advances in surgical procedures, integration of 3D imaging for diagnostic purposes, and progress in care models that prioritize the patient.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21112&type=smp

Which Key Factors Are Fueling Growth In The Benign Prostatic Hyperplasia Treatment Market?

The increasing preference for minimally invasive surgeries is forecasted to fuel the benign prostatic hyperplasia treatment market’s expansion. These surgeries involve fewer or no incisions by utilizing unique instruments, thereby reducing pain, recovery duration, and complication risks. The growing popularity of such procedures lies in their inherent advantages, including lesser recovery periods, minimized discomfort, fewer complication risks, and better cosmetic results. The use of minimally invasive procedures in treating benign prostatic hyperplasia results in swifter recovery, lower complication chances, and efficient symptom alleviation, therefore improving the overall surgery results. As an illustration, the American Society of Plastic Surgeons (ASPS), a professional association based in the US, stated that in 2022, there were 23,672,269 cosmetic minimally invasive procedures performed worldwide. The treatments encompassed procedures like neuromodulator injections, lip augmentation, and non-invasive skin tightening. Consequently, the adoption surge of minimally invasive surgeries is propelling the benign prostatic hyperplasia treatment market’s growth.

How Is The Benign Prostatic Hyperplasia Treatment Market Categorized Across Applications And Types?

The benign prostatic hyperplasia treatmentmarket covered in this report is segmented –

1) By Treatment: Minimal Invasive Surgery; Invasive Surgery

2) By Therapeutic Class: Alpha Blockers; 5-Alpha Reductase Inhibitors; Phosphodiesterase-5 Inhibitors; Other Therapeutic classes

3) By End User: Home Healthcare; Hospitals And Clinics; Research And Manufacturing

Subsegments:

1) By Minimal Invasive Surgery: Transurethral Resection of the Prostate (TURP); Laser Surgery; Prostatic Urethral Lift; Transurethral Incision of the Prostate (TUIP); Microwave Therapy

2) By Invasive Surgery: Open Prostatectomy; Robotic Prostatectomy

How Are Industry Trends Steering The Expansion Of The Benign Prostatic Hyperplasia Treatment Market?

Leading businesses within the benign prostatic hyperplasia treatment market are focusing on the creation of novel solutions, such as minimally invasive procedures, to improve patient results and decrease recuperation periods. These methods involve little to no incisions, thereby reducing trauma, discomfort, and risks of complications while offering a quicker recovery compared to older surgical treatments. For example, in December 2022, the UroLift System was introduced by Teleflex Incorporated, an American medical device firm, as a treatment option for benign prostatic hyperplasia. This system employs small, permanent implants to relocate enlarged prostate tissue, providing substantial symptom alleviation without the necessity for tissue removal, cutting, or heating. This outpatient procedure guarantees a speedy recovery, maintains sexual performance, and yields superior symptom relief compared to conventional BPH drugs, with side effects usually dissipating within a two to four-week timeframe.

Which Firms Are Making The Biggest Impact In The Benign Prostatic Hyperplasia Treatment Market?

Major companies operating in the benign prostatic hyperplasia treatment market are Pfizer Inc., Merck And Co Inc, AbbVie Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline Public Limited Company, Medtronic Public Limited Company, Mezzion Pharma Co Ltd, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Boston Scientific Corporation, Astellas Pharma Inc., Olympus Corporation, Coloplast Group, Teleflex Incorporated, Cook Medical Incorporated, AngioDynamics, Inc., HistoSonics Inc, Urovant Sciences Ltd, UroGen Pharma Ltd., Urologix Inc, Zenflow Inc, Butterfly Medical Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/benign-prostatic-hyperplasia-treatment-global-market-report

Which Region Holds The Greatest Opportunity For Benign Prostatic Hyperplasia Treatment Market Expansion?

North America was the largest region in the benign prostatic hyperplasia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the benign prostatic hyperplasia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21112&type=smp

Browse Through More Reports Similar to the Global Benign Prostatic Hyperplasia Treatment Market 2025, By The Business Research Company

Benign Prostatic Hyperplasia Bph Treatment Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/benign-prostatic-hyperplasia-bph-treatment-devices-and-equipment-global-market-report

Urinary Incontinence And Pelvic Organ Prolapse Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/urinary-incontinence-and-pelvic-organ-prolapse-devices-and-equipment-global-market-report

Urinary Stone Treatment Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/urinary-stone-treatment-devices-and-equipment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Forecasted Market Size Estimates For The Benign Prostatic Hyperplasia Treatment Market Between 2025 And 2029?

The benign prostatic hyperplasia treatment market has experienced significant expansion in recent years. It is projected to expand from $8.23 billion in 2024 to $8.69 billion in 2025, achieving a compound annual growth rate (CAGR) of 5.5%. This historical increase can be attributed to factors such as rising awareness and screening efforts, the increasing prevalence of BPH, enhanced healthcare knowledge, improvements in healthcare infrastructure, and an expanding elderly population.

The benign prostatic hyperplasia treatment market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $10.74 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 5.5%. Several factors contribute to this growth during the forecast period, including the increasing embrace of minimally invasive procedures, an expanding elderly population, greater access to sophisticated treatment alternatives, an intensified emphasis on patient-focused care, and a rising incidence of co-existing medical conditions. Key trends anticipated during this period encompass the development of targeted therapeutic approaches, the incorporation of digital health technologies, advancements in surgical interventions, the integration of 3D imaging for diagnostic purposes, and novel approaches in patient-centered care models.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21112&type=smp

Which Major Market Drivers Are Shaping The Future Of The Benign Prostatic Hyperplasia Treatment Market?

The expanding integration of minimally invasive surgical techniques is anticipated to fuel the expansion of the benign prostatic hyperplasia treatment market. These surgical interventions are characterized by their minimal or absent incision requirements, employing specialized tools to shorten recovery periods, alleviate discomfort, and mitigate the likelihood of complications. The increasing acceptance of minimally invasive surgeries stems from their advantages, including quicker recuperation, diminished pain, a decreased risk of adverse events, and superior aesthetic results. When applied to benign prostatic hyperplasia treatment, minimally invasive procedures offer patients quicker healing, a reduced chance of complications, and significant symptom alleviation, thereby improving the overall success of surgical interventions. Illustratively, data from September 2023, sourced from the American Society of Plastic Surgeons (ASPS), a US-based professional association, indicated that 23,672,269 cosmetic minimally invasive procedures were carried out worldwide in 2022, encompassing treatments like neuromodulator injections, lip augmentation, and non-invasive skin tightening. Consequently, the growing preference for minimally invasive surgical techniques is a key factor propelling the expansion of the benign prostatic hyperplasia treatment market.

What Are The Key Segments In The Benign Prostatic Hyperplasia Treatment Market?

The benign prostatic hyperplasia treatmentmarket covered in this report is segmented –

1) By Treatment: Minimal Invasive Surgery; Invasive Surgery

2) By Therapeutic Class: Alpha Blockers; 5-Alpha Reductase Inhibitors; Phosphodiesterase-5 Inhibitors; Other Therapeutic classes

3) By End User: Home Healthcare; Hospitals And Clinics; Research And Manufacturing

Subsegments:

1) By Minimal Invasive Surgery: Transurethral Resection of the Prostate (TURP); Laser Surgery; Prostatic Urethral Lift; Transurethral Incision of the Prostate (TUIP); Microwave Therapy

2) By Invasive Surgery: Open Prostatectomy; Robotic Prostatectomy

What Are The Latest Industry Trends Transforming The Benign Prostatic Hyperplasia Treatment Market?

Leading companies in the benign prostatic hyperplasia treatment market are prioritizing the creation of innovative solutions, including minimally invasive procedures, to enhance patient outcomes and shorten recovery periods. These procedures involve minimal or no incisions, thereby reducing trauma, pain, and complications while enabling a faster recovery than traditional surgical methods. For instance, in December 2022, Teleflex Incorporated, a U.S.-based medical device company, launched the UroLift System designed to treat benign prostatic hyperplasia. This system utilizes small, permanent implants to reposition enlarged prostate tissue, offering significant symptom relief without the need for tissue removal, cutting, or heating. This outpatient treatment ensures rapid recuperation, preserves sexual function, and delivers superior symptom relief compared to traditional BPH medications, with side effects typically resolving within two to four weeks.

Which Industry Leaders Are Driving Innovation Across The Benign Prostatic Hyperplasia Treatment Market?

Major companies operating in the benign prostatic hyperplasia treatment market are Pfizer Inc., Merck And Co Inc, AbbVie Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline Public Limited Company, Medtronic Public Limited Company, Mezzion Pharma Co Ltd, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Boston Scientific Corporation, Astellas Pharma Inc., Olympus Corporation, Coloplast Group, Teleflex Incorporated, Cook Medical Incorporated, AngioDynamics, Inc., HistoSonics Inc, Urovant Sciences Ltd, UroGen Pharma Ltd., Urologix Inc, Zenflow Inc, Butterfly Medical Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/benign-prostatic-hyperplasia-treatment-global-market-report

Which Region Currently Holds The Largest Share Of The Benign Prostatic Hyperplasia Treatment Market?

North America was the largest region in the benign prostatic hyperplasia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the benign prostatic hyperplasia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Benign Prostatic Hyperplasia Treatment Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21112&type=smp

Browse Through More Reports Similar to the Global Benign Prostatic Hyperplasia Treatment Market 2025, By The Business Research Company

Benign Prostatic Hyperplasia Bph Treatment Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/benign-prostatic-hyperplasia-bph-treatment-devices-and-equipment-global-market-report

Urinary Incontinence And Pelvic Organ Prolapse Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/urinary-incontinence-and-pelvic-organ-prolapse-devices-and-equipment-global-market-report

Urinary Stone Treatment Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/urinary-stone-treatment-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Benign Prostatic Hyperplasia Treatment Market Through 2034?

Over the past few years, there has been a significant expansion in the market size for benign prostatic hyperplasia treatment. It is projected to increase from $8.23 billion in 2024 to $8.69 billion in 2025, showcasing a compound annual growth rate (CAGR) of 5.5%. Factors such as enhanced awareness and targeted screening initiatives, a higher incidence rate of BPH, an increased understanding of healthcare, improved healthcare facilities, and an aging population, have contributed to the growth observed during the historic period.

The market size for benign prostatic hyperplasia treatment is projected to experience substantial growth in the near future. It is anticipated to increase to$10.74 billion in 2029 with a compound annual growth rate (CAGR) of 5.5%. This advancement during the forecasting period may be due to the growing use of minimally invasive practices, an increasing count of elderly patients, improved availability of cutting-edge treatment choices, an intensified focus on patient-oriented care, and a surge in the number of related health complications. Future trends within the forecasted timeframe encompass the development of tailored therapies, incorporation of online health solutions, advancements in surgical alternatives, assimilation of 3D imaging for diagnostic purposes, and innovation in patient-centric care frameworks.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21112&type=smp

What External and Internal Drivers Are Contributing to the Growth of theBenign Prostatic Hyperplasia Treatment Market?

The growth of the benign prostatic hyperplasia treatment market is expected to be bolstered by the increasing use of minimally invasive surgeries. These are surgical procedures that involve small or no incisions made using specialized instruments, with the added advantages of quicker recovery time, less pain and a lesser likelihood of complications. Shifting preferences toward minimally invasive surgeries have been attributed to benefits like faster recovery, alleviated pain, minimization of complication risks, and enhanced aesthetic results. Implementing minimally invasive surgeries for treating benign prostatic hyperplasia results in lesser recovery time, reduced likelihood of complications, and practical symptom relief, thereby improving overall surgical results. For instance, the American Society of Plastic Surgeons (ASPS), a professional association located in the US, stated in September 2023 that in 2022, globally, there were 23,672,269 cosmetic minimally invasive procedures undertaken, which included treatments like neuromodulator injections, lip augmentation, and non-invasive skin tightening. Therefore, the increasing acceptance of minimally invasive surgeries is fueling the expansion of the benign prostatic hyperplasia treatment market.

What Segment Types Define the Benign Prostatic Hyperplasia Treatment Market Structure?

The benign prostatic hyperplasia treatmentmarket covered in this report is segmented –

1) By Treatment: Minimal Invasive Surgery; Invasive Surgery

2) By Therapeutic Class: Alpha Blockers; 5-Alpha Reductase Inhibitors; Phosphodiesterase-5 Inhibitors; Other Therapeutic classes

3) By End User: Home Healthcare; Hospitals And Clinics; Research And Manufacturing

Subsegments:

1) By Minimal Invasive Surgery: Transurethral Resection of the Prostate (TURP); Laser Surgery; Prostatic Urethral Lift; Transurethral Incision of the Prostate (TUIP); Microwave Therapy

2) By Invasive Surgery: Open Prostatectomy; Robotic Prostatectomy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21112&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Benign Prostatic Hyperplasia Treatment Market?

North America was the largest region in the benign prostatic hyperplasia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the benign prostatic hyperplasia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Benign Prostatic Hyperplasia Treatment Market?

Key players in the benign prostatic hyperplasia treatment industry are striving to create innovative solutions, such as minimally invasive procedures, to improve patient outcomes and reduce recovery durations. These types of procedures use small or no incisions, resulting in less trauma, pain, and potential complications, while also promoting a quicker recovery than conventional surgical methods. For instance, in December 2022, Teleflex Incorporated, a medical device firm based in the US, introduced the UroLift System designed for treating benign prostatic hyperplasia. This system employs tiny, permanent implants to adjust the position of enlarged prostate tissue, providing substantial relief from symptoms without the need for tissue removal, cutting, or heating. This outpatient procedure allows for a swift recovery, maintains sexual function, and results in superior relief from symptoms compared to usual BPH medicines. Known side effects usually clear up within two to four weeks.

View the full report here:

https://www.thebusinessresearchcompany.com/report/benign-prostatic-hyperplasia-treatment-global-market-report

What Is the Definition of the Benign Prostatic Hyperplasia Treatment Market?

Benign prostatic hyperplasia (BPH) treatment refers to medical, minimally invasive, and surgical approaches used to manage the symptoms of an enlarged prostate. BPH is a common condition in aging men, leading to urinary issues such as frequent urination, weak stream, and incomplete bladder emptying.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21112

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Benign Prostatic Hyperplasia Treatment Market from 2024 to 2025?

In recent times, the market for benign prostatic hyperplasia treatment has witnessed significant growth. It is projected to increase from $8.23 billion in 2024 to $8.71 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.9%. Factors such as heightened awareness and screening initiatives, surge in the cases of BPH, enhanced consciousness about healthcare, betterment of healthcare infrastructure and an aging population have contributed to this growth during the historical period.

What Is the Projected Market Size of the Benign Prostatic Hyperplasia Treatment Market?

The market size for benign prostatic hyperplasia treatment is projected to experience significant expansion in the coming years. It is set to escalate to $10.83 billion by 2029, with a compound annual growth rate (CAGR) of 5.6%. The resurgence of this market in the forecast period can be associated with the increasing adoption of minimally invasive procedures, growing count of elderly patients, enhanced availability of sophisticated treatment methods, a rising emphasis on patient-centric care, and an increase in the incidence of comorbidities. The forecast period will witness significant trends such as the development of focused therapies, digital health solutions integration, advancements in surgical methods, implementation of 3D imaging for diagnosis, and innovations in patient-centered care structure.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21112&type=smp

Who are the Major Competitors in the Benign Prostatic Hyperplasia Treatment Market Outlook?

Major companies operating in the benign prostatic hyperplasia treatment market are Pfizer Inc., Merck And Co Inc, AbbVie Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline Public Limited Company, Medtronic Public Limited Company, Mezzion Pharma Co Ltd, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Boston Scientific Corporation, Astellas Pharma Inc., Olympus Corporation, Coloplast Group, Teleflex Incorporated, Cook Medical Incorporated, AngioDynamics, Inc., HistoSonics Inc, Urovant Sciences Ltd, UroGen Pharma Ltd., Urologix Inc, Zenflow Inc, Butterfly Medical Ltd.

What Is Fueling Growth in the Benign Prostatic Hyperplasia Treatment Market?

The increasing acceptance of minimally invasive surgical procedures is projected to be a key driver in the expansion of the benign prostatic hyperplasia treatment market in the future. These surgeries, which involve small or no incisions, use specific tools to lessen recovery time, pain, and potential complications. The surge in the use of minimally invasive surgeries can be ascribed to benefits like shorter recuperation periods, minimised discomfort, decreased risk of complications, and superior cosmetic results. Treatment for benign prostatic hyperplasia using these surgical methods offers benefits like faster recovery, lesser chances of complications, effective resolution of symptoms, boosting overall surgical results. An example is from September 2023, where the American Society of Plastic Surgeons (ASPS) revealed that in 2022, around 23,672,269 cosmetic minimally invasive treatments were conducted worldwide. These treatments included neuromodulator injections, lip augmentations, and non-invasive skin tightening. Hence, the growing adoption of minimally invasive surgical procedures is fuelling the growth of the benign prostatic hyperplasia treatment market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21112&type=smp

Which Benign Prostatic Hyperplasia Treatment Market Segments Are Growing the Fastest?

The benign prostatic hyperplasia treatment market covered in this report is segmented –

1) By Treatment: Minimal Invasive Surgery, Invasive Surgery

2) By Therapeutic Class: Alpha Blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Other Therapeutic classes

3) By End User: Home Healthcare, Hospitals And Clinics, Research And Manufacturing

Subsegments:

1) By Minimal Invasive Surgery: Transurethral Resection of the Prostate (TURP), Laser Surgery, Prostatic Urethral Lift, Transurethral Incision of the Prostate (TUIP), Microwave Therapy

2) By Invasive Surgery: Open Prostatectomy, Robotic Prostatectomy

Which Industry Trends Are Shaping the Future of the Benign Prostatic Hyperplasia Treatment Market?

Key players in the benign prostatic hyperplasia treatment industry are focusing on the creation of novel solutions, for example, minimally invasive procedures, to improve patient results and reduce recovery durations. These methods entail minor or no surgical cuts, thus reducing trauma, discomfort, and risks, while also facilitating a quicker healing process compared to conventional surgical techniques. Take for example, Teleflex Incorporated, a medical device establishment based in the U.S, which introduced the UroLift System for treating benign prostatic hyperplasia in December 2022. Here, tiny permanent implants are used to reposition the enlarged prostate tissue, providing substantial symptom relief without requiring tissue removal, incision, or heating. This outpatient procedure guarantees speedy recovery, maintains sexual functionality, and offers superior symptom relief relative to traditional BPH medications, with side effects typically subsiding within a span of two to four weeks.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/benign-prostatic-hyperplasia-treatment-global-market-report

Which Countries Are Leading the Benign Prostatic Hyperplasia Treatment Market?

North America was the largest region in the benign prostatic hyperplasia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the benign prostatic hyperplasia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21112

This Report Delivers Insight On:

1. How big is the benign prostatic hyperplasia treatment market, and how is it changing globally?

2. Who are the major companies in the benign prostatic hyperplasia treatment market, and how are they performing?

3. What are the key opportunities and risks in the benign prostatic hyperplasia treatment market right now?

4. Which products or customer segments are growing the most in the benign prostatic hyperplasia treatment market?

5. What factors are helping or slowing down the growth of the benign prostatic hyperplasia treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model